Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd (DRTS) is a clinical-stage oncology innovator advancing Alpha DaRT technology for targeted solid tumor treatment. This page consolidates all official corporate communications and verified news coverage related to clinical developments, regulatory progress, and strategic initiatives.
Investors and researchers will find timely updates on clinical trial outcomes, regulatory submissions, and technology partnerships critical for evaluating the company’s therapeutic pipeline. The curated news collection serves as a centralized resource for tracking milestones in alpha-radiation oncology solutions.
Content spans phase trial results, manufacturing expansions, and peer-reviewed study publications, providing comprehensive insight into the company’s progress. All materials are vetted for relevance to investment analysis and therapeutic development.
Bookmark this page for efficient monitoring of DRTS’ advancements in localized radiotherapy. Combine regular reviews with SEC filings and medical journals for complete due diligence.
Alpha Tau Medical, a leader in alpha-radiation cancer therapy, announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024. Their CFO, Raphi Levy, will present a corporate overview and update at the event scheduled from 1:30 to 1:55 PM EST in New York. Levy will also be available for one-on-one meetings with investors during the conference. Attendees are encouraged to contact their Jefferies representative to schedule a session.
Alpha Tau Medical reported its Q1 2024 financials and provided a corporate update. The company presented preclinical data showcasing an abscopal immune effect in pancreatic murine tumor models at ESTRO 2024. The first patient in a liver metastases study was treated at McGill University Health Center, with recruitment ongoing for multiple trials. Financially, the company recorded R&D expenses of $6.4 million, marketing expenses of $0.5 million, and G&A expenses of $1.4 million, resulting in a net loss of $8.0 million. Alpha Tau holds $80.7 million in cash, projected to fund operations for at least two years.
Alpha Tau Medical announced the treatment of the first patient with liver cancer metastases using their innovative alpha-radiation cancer therapy, Alpha DaRT. The feasibility and safety study is being conducted at McGill University Health Center in Montreal, Canada. The trial aims to recruit up to 10 patients for a two-staged hepatectomy to resect liver metastases of colorectal cancer. The study will assess the feasibility and safety of delivering Alpha DaRT sources into the liver metastases, as well as its efficacy in terms of radiological and pathological response. CEO Uzi Sofer expressed optimism about the trial's potential to provide new therapeutic options for patients with liver metastases and other challenging cancers.
Alpha Tau Medical presented new preclinical data at the 2024 ESTRO Congress, showcasing the abscopal immune effect of Alpha DaRT in pancreatic murine tumor models. The data revealed a significant reduction in distant tumor growth rate, indicating potential benefits for future clinical trials and patient outcomes. CEO Uzi Sofer highlighted the promising results, emphasizing the therapy's potential in combination with immunotherapy.
Alpha Tau Medical announced that CFO Raphi Levy will present at investor conferences in May 2024. The company, known for its alpha-radiation cancer therapy Alpha DaRT™, will participate in events like Guggenheim Securities Radiopharmaceuticals Day and H.C. Wainwright BioConnect Investor Conference.
FAQ
What is the current stock price of Alpha Tau Medical (DRTS)?
What is the market cap of Alpha Tau Medical (DRTS)?
